Drugs / GC2129A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05729386 | Feb → Apr 2023 | — | GC Biopharma Corp | Unknown | No outcome recorded |
| Phase 1 | NCT05703984 | Jan → Apr 2023 | — | GC Biopharma Corp | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC2129A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703984 ↗ |
| Route | Oral | “oral administration of GC2129A” NCT05703984 ↗ |